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Abstract
Background: Poncirin is flavanone derivative (isolated from Poncirus trifoliata) with known pharmacological
activities such as anti-tumor, anti-osteoporotic, anti-inflammatory and anti-colitic. The present study aimed to
explore the anti-allodynic and anti-hyperalgesic potentials of poncirin in murine models of inflammatory pain.
Methods: The analgesic potential of poncirin was evaluated in formalin-, acetic acid-, carrageenan- and Complete
Freund’s Adjuvant (CFA)-induced inflammatory pain models in mice. Anti-allodynic and anti-hyperalgesic activities
were measured using Von Frey filaments, Randall Selitto, hotplate and cold acetone tests. The serum nitrite levels
were determined using Griess reagent. The Quantitative Real-time PCR (qRT-PCR) was performed to assess the
effect of poncirin on mRNA expression levels of inflammatory cytokines and anti-oxidant enzymes.
Results: Intraperitoneal administration of poncirin (30 mg/kg) markedly reduced the pain behavior in both acetic
acid-induced visceral pain and formalin-induced tonic pain models used as preliminary screening tools. The
poncirin (30 mg/kg) treatment considerably inhibited the mechanical hyperalgesia and allodynia as well as thermal
hyperalgesia and cold allodynia. The qRT-PCR analysis showed noticeable inhibition of pro-inflammatory cytokines
(mRNA expression levels of TNF-α, IL-1β and IL-6) (p < 0.05) in poncirin treated group. Similarly, poncirin treatment
also enhanced the mRNA expressions levels of anti-oxidant enzymes such as transcription factor such as nuclear
factor (erythroid-derived 2)-like 2 (Nrf2) (p < 0.05), heme oxygenase (HO-1) (p < 0.05) and superoxide dismutase
(SOD2) (p < 0.05). Chronic treatment of poncirin for 6 days did not confer any significant hepatic and renal toxicity.
Furthermore, poncirin treatment did not altered the motor coordination and muscle strength in CFA-induced
chronic inflammatory pain model.
Conclusion: The present study demonstrated that poncirin treatment significantly reduced pain behaviors in all
experimental models of inflammatory pain, suggesting the promising analgesic potential of poncirin in
inflammatory pain conditions.
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Background
Pain is the major protective response that is initiated by
peripheral sensory neurons to protect the organism from
any harm by infection or tissue injury [1]. Pain helps the
body to take corrective actions in the presence of any
noxious stimuli. However, the presence of pain is not
always beneficial, in certain clinical scenarios; pain
increases the suffering when there is a dysfunction in
nociceptive pathways for example in neuropathic pain
and abnormal central amplifications syndromes [1].
Inflammatory pain results whenever injury to the tissues
ensues, causing the release of inflammatory mediators,
which decreases pain threshold by increasing the
transduction of painful stimuli [2]. These inflammatory
mediators including tumor necrosis factor-α (TNF-α),
interleukin-1β (IL-1β) and IL-6, reduces pain threshold
by directly sensitizing nociceptors and causing its in-
creased responsiveness leading to a state of hyperalgesia
and allodynia [3, 4]. In addition to directly activating
nociceptive fibers, these cytokines also potentiate the
inflammatory responses and increase the release of
proalgesic agents including nerve growth factor (NGF),
extracellular protons, bradykinin, and prostaglandins,
resulting in pain hypersensitivity [5]. These inflamma-
tory mediators are also linked with an increased tran-
scription of various inflammatory genes through
transcription factors including mitogen activated protein
kinases (MAPKs), cAMP response element-binding
protein (CREB) and Nuclear factor kappa B (NF-κB),
which further aggravates the immune and pain re-
sponses by altering the neuronal threshold [5–7].
Although, painful conditions either acute or chronic
inflammatory pain, constitute a major health prob-
lem. There is still need for safe and effective therapeutic
options. For example, non-steroidal anti-inflammatory
drugs (NSAIDs) are widely used for the management of
inflammatory pain conditions, are unable to completely
abolish pain and are associated with several serious ad-
verse effects including gastrointestinal bleeding and
renal toxicity [8]. On the other hand, opioid analgesic
represents a potent class of analgesics are also associated
with major adverse effects including physical and psy-
chological dependence, lethargy, euphoria, respiratory
depression [8]. Current therapies available for treating
acute and chronic inflammatory are inadequate and
there is a need of newer and safer analgesics and anti-in-
flammatory drugs, that have better efficacy and tolerabil-
ity [9, 10].
Medicinal plants have been used for centuries for pain
management, which can be used as a potential source
for the development of novel analgesics for treating pain
[11]. Poncirin is a flavanone derivative obtained from
dried immature fruits of Poncirus trifoliata. Poncirus
trifoliata belongs to genus Citrus, which have been used
in Chinese medicine for the treatment of asthma and in-
flammation [12]. Several studies reported that poncirin
exhibit anti-inflammatory [13], anti-tumor [14], anti-
osteoporotic activity [15] and anti-colitic properties
(Kang and Kim 2016). Therefore, in the present study
various animal models of pain were carried out to assess
the anti-allodynic, anti-hyperalgesic and anti-nociceptive
properties of poncirin as a potential new analgesic to
treat different types of inflammatory pain.
Methods
Chemicals and reagents
Carrageenan, Complete Freund’s adjuvant (CFA), forma-
lin, acetic acid, dexamethasone, Griess reagent, acetone,
piroxicam, and poncirin were obtained from Sigma
chemical company (St. Louis, MO, USA). Trizol reagent
was obtained from Invitrogen (USA).
Ethics approval and consent to participate
All procedures were complied with “Animal care guide-
lines of QAU” Islamabad. The study was also approved
by Bioethical Committee (Approval No: BEC-FBS-QAU
2017–2) of QAU University, Islamabad. All the experi-
ments were designed to cause minimum harm to
animals.
Animals
All experiments were performed on male albino (BALB/
c mice, 4–5 weeks of age, weighing 25–30 g), purchased
from National Institute of Health (NIH), Islamabad,
Pakistan. All behavioral assays were carried out in patho-
gen-free environment of laboratory of Pharmacology, De-
partment of Pharmacy, QAU, Islamabad, Pakistan. Seven
animals were housed per cage in controlled temperature
and humidity, with free access to food and water. All ex-
periments were performed between 8:00 a.m. to 6:00 p.m.
During the current study, fresh/separate set of animals
were procured for each model (acetic acid, formalin, carra-
geenan and CFA) and used once as per institutional ethical
guidelines.
Experimental groups and treatment protocols
The animals were randomly arranged into various
groups and each group consists of 6–7 animals. The ve-
hicle control received only normal saline with 2% DMSO
and no other treatment or inducer was given. The nega-
tive control group received either acetic acid, formalin,
Carrageenan or CFA and no other treatment was admin-
istered. The positive control either received Piroxicam
(in case of formalin and acetic acid-induced models),
while dexamethasone was administered in case of the
Carrageenan and CFA-induced inflammatory models.
The treatment control received the poncirin at three dif-
ferent doses such as 5mg/kg, 15 mg/kg and 30mg/kg in
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case of formalin, acetic acid and Carrageenan-induced
models, while only 30 mg/kg dose was administered to
only CFA-induced models. The inclusion and exclusion
criteria was followed as reported previously [16]. The
animals were anesthetized with the Xylazine + ketamine
injection (16 mg + 60mg, i.p) to avoid distress to the
mice (to make them unconscious and reduce the painful
feeling associated with the euthanasia) and then CO2
chamber was used to euthanize the mice. The
institutional ethical committee regulated the overall
process of euthanasia. Prior to the disposal, the animal
death was confirmed by observing the movement, heart-
beat, respiration and eye reflex.
Randomization, blinding and sample size selection
The animals were assigned to various groups randomly
as reported previously [16]. Similarly, to avoid experi-
mental biasness double blindness was maintained during
the whole experiment as mentioned [16]. The sample
size (n = 6–7) was selected according to the previously
established protocols [16–19]. At the end of the experi-
ments the mice were euthanized using CO2 chamber.
Acetic acid-induced visceral pain model
Acetic acid-induced writhing test was performed in mice
as described previously [20]. The acetic acid-induced
pain model simulate the visceral pain model and initi-
ated by the release of inflammatory mediators, which
trigger the sensitization of the sensitization of nocicep-
tors [20, 21]. Briefly, acetic acid (0.8% v/v, 10 ml/kg) was
injected into peritoneal cavity of the mice. Mice were
then placed in large glass cylinder (10 cm diameter) and
writhing response was measured i.e. number of writhes
occurring between 0 and 30min after acetic acid injec-
tion. Drugs were administered by i.p route 40 min prior
to acetic acid induction, control group was treated with
vehicle (2% DMSO in 300 μl saline, i.p), positive control
was treated with piroxicam (5 mg/kg, i.p) and the
treatment group received poncirin (5 mg/kg, 15 mg/kg
or 30mg/kg, i.p).
Formalin-induced tonic pain model
Paw licking was induced by intraplantar injection of for-
malin as described previously with some modification
[22]. Before the initiation of formalin-induction, the
mice were transferred to the formalin testing boxes and
observed for 30 min. Following the induction of the for-
malin-induced nociception, animals were further
observed for 30 min and the total time taken was 60min
as reported previously with necessary modification [23].
Mice were observed for first 10 min (early phase) and
from 10 to 30 min (late phase) and total time spent in
licking the injected paw was calculated for both phases.
The mice were administered drugs through i.p. route 40
min prior to formalin induction. Control group was
treated with vehicle (2% DMSO in 300 μl saline, i.p) and
positive control was treated with piroxicam (5 mg/kg),
while treatment group received poncirin (5 mg/kg, 15
mg/kg or 30mg/kg, i.p).
Carrageenan-induced acute inflammatory pain model
The anti-inflammatory potential of the poncirin
against the Carrageenan-induced inflammatory model
was explored [24]. The animals were randomly
divided into various groups as described above. The
Carrageenan-induced inflammation was established by
injecting 1% carrageenan solution into the right hind
paw as reported [24].
Assessment of mechanical hyperalgesia in carrageenan-
induced inflammatory pain
The mechanical hyperalgesia test was performed by
using Randall Selitto (Digital Paw Pressure Randall
Selitto Meter, IITC Life Science Inc. Wood land Hills,
CA) according to the method described previously
[24–26]. Animals were pretreated with poncirin (30
mg/kg) or vehicle (2% DMSO in 300 μl saline, i.p) or
dexamethasone (5 mg/kg) 1 h before the injection of
carrageenan (100 μg/paw). The anti-hyperalgesic
response of poncirin was recorded 4 h after the carra-
geenan injection.
Assessment of mechanical allodynia in carrageenan-
treated mice
In order to evaluate the anti-allodynic effects of poncirin
in acute inflammatory pain model was noted 4 h after
carrageenan injection (100 μg /paw). One day before the
experiment, baseline withdrawal threshold was deter-
mined for all animals. On the day of the experiment,
animals were treated with poncirin (30 mg/kg) or
vehicle (2% DMSO in 300 μl saline, i.p) or
dexamethasone (5 mg/kg) 1 h before the injection of
carrageenan. Mechanical allodynia was measured in
all the treated groups using previously described
protocol [27, 28].
Assessment of thermal hyperalgesia in carrageenan-
treated mice
Spontaneous nociception to heat stimuli was measured
according to previously described methods [29]. Mice
were placed in quiet room 30min before starting the test
and were observed for the signs of the nociception
including licking of the hind paws. The response latency
was considered as nociceptive behavior with a cut off
time of 35 s, in order to avoid any tissue damage.
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Paw edema test in carrageenan-treated mice
Paw edema was measured in carrageenan-induced
inflammatory pain model according to the methods
previously described [26, 28]. Briefly, paw thickness was
measured by using a dial thickness gauge (No. 2046F,
Mitutoyo, Kawasaki, Japan) one day before and after
carrageenan (100 μg/paw) administration for all the
treated groups.
CFA-induced chronic inflammatory pain model
For the evaluation of anti-hyperalgesic activity of pon-
cirin in chronic inflammatory pain model, CFA-induced
pain model was employed [28, 30]. For the evaluation of
the effect of poncirin on acute inflammation and pain,
readings were taken at 2, 4 and 6 h post CFA injection.
While to investigate the effect of chronic treatment of
poncirin on mechanical and thermal sensitivity, mice
were treated with poncirin once a day for the period of
6 days. However, the dose of poncirin was skipped at day
5 in order to check any tolerance effects (to see whether
the effect of the drug remains persistent or it should be
administered daily to achieve the response) as described
previously [28].
Assessment of mechanical hyperalgesia and allodynia
induced by CFA
To evaluate mechanical hyperalgesia induced by CFA,
mice were treated with poncirin (30 mg/kg), vehicle (2%
DMSO in 300 μl saline, i.p) or dexamethasone (5 mg/kg)
by intra peritoneal route 40 min before the injection of
CFA (20 μl/paw). One day before the experiment,
baseline withdrawal threshold was determined for all an-
imals. For the evaluation of acute effects of poncirin on
pain profile, readings were taken at 2, 4 and 6 h post
CFA injection. Mechanical hyperalgesia was measured
by Randall Selitto (Digital Paw Pressure Randall Selitto
Meter, IITC Life Science Inc. Wood land Hills, CA),
while mechanical allodynia was measured using von Frey
hair filament.
Assessment of thermal hyperalgesia induced by CFA
Hotplate test was carried out in mice model of CFA
induced inflammatory pain as described previously
[29]. One day before the experiment, baseline with-
drawal threshold was determined for all animals.
Readings were taken at 2, 4 and 6 h post CFA injec-
tion in order to evaluate the effect of poncirin in the
acute phase, while readings were taken for 6 consecu-
tive days for the chronic study. The dose of the pon-
cirin was skipped at day 5 to assess the tolerance
effect as reported previously [28].
Assessment of cold allodynia in CFA-treated mice-cold
acetone test
Cold acetone test was carried out in mice model of
CFA-induced inflammatory pain as described previously
[31, 32]. One day before the experiment, baseline
withdrawal threshold was determined for all animals.
Mice were placed in glass cylinders, and the noxious
cold stimulus was applied in form of brief spray of acet-
one to the ventral surface of the right hind paw. The
nociceptive response, which included licking or biting,
was measured for 25 s as mentioned earlier [28].
Muscle strength and motor activity
The muscle strength of mice was determined by using
weights test and Kondziela’s inverted screen tests, in
order to assess the effect of poncirin on motor activity
of mice [33]. In Kondziela’s screen test, each mouse was
placed in the center of wire mesh screen and the screen
was inverted, which was held 40–50 cm above the pad-
ded surface. Time taken by mice to hold the inverted
screen was recorded using a digital stopwatch and score
was assigned according to the protocol described else-
where [33]. Weight test was performed for measuring




Griess reagents was used to determine the serum nitric
oxide (NO) as reported previously [34, 35]. The blood
was centrifuged at 2500 rpm for 10min following collec-
tion of the blood directly from the cardiac puncture and
NO was determined as described [34, 35].
Extraction of mRNA and q-RT-PCR
At day 6 of the CFA administration the animals were
anesthetized with Xylazine + ketamine (16 mg + 60 mg,
i.p) to remove the paw tissue. Following removal of paw
tissue, the animals were euthanized in the CO2 chamber
[36]. Mice paw were used for the extraction of total
RNA using Trizol Reagent according to manufacturer
instructions (Invitrogen Life Technologies, Carlsbad,
CA, USA) as described previously [28]. Briefly, q-RT-
PCR analysis for various target genes (TNF-α, IL-1β,
IL-6, Nrf2, HO-1, SOD2, VEGF, β-actin) mRNA was
performed using Applied Biosystems (AB) detection
instruments and software as described previously [28].
The forward and revere primers used are listed in the
Table 1.
Renal and liver toxicity
Biochemical tests were performed using serum samples
for assessment of RFTs and LFTs (Renal function tests
and liver function tests) at day 6 of the CFA
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administration. Serum Aspartate Aminotransferase
(AST), Alanine Aminotransferase (ALT) and creatinine
concentration were determined as indicators of liver and
kidney functions respectively [37, 38].
Histopathological and X-ray examination of inflamed paws
To observe the effect of daily treatment of poncirin on
mice paw tissue, histopathological and radiological ana-
lysis of the paw tissues were performed [21]. At day 6 of
the CFA administration the animals were anesthetized
with Xylazine + ketamine (16 mg/kg + 60mg/kg, i.p) and
were euthanized in the CO2 chamber as mentioned [21].
After removal, each paw was washed using saline and
then fixed in 10% formalin solution, dehydrated and
embedded in paraffin according to the methods de-
scribed previously [21]. Paw tissue blocks sections were
made of 4 μm thickness, stained with hematoxylin-eosin
and observed by microscopy (40×) as per reported
protocols [21]. Similarly, the X-ray analysis (Philips 612
machine 40 kW for 0.01 s) was performed as to assess
the soft tissue swelling and bone erosion as described
previously [21].
Statistical analysis
All results are expressed as mean ± SEM. The differences
between the control and normal groups were tested by
one-way analysis of variance (ANOVA) followed by
Student’s t-test using SPSS (version 10.0, Chicago, IL). A
value of p < 0.05 was chosen as the criterion for statis-
tical significance. The graphs were plotted using Sigma
plot version 12.0, Chicago, USA.
Results
Poncirin inhibits abdominal constriction induced by
acetic acid
In the first set of experiments, the anti-nociceptive effect
of poncirin was assessed in acetic acid-induced visceral
pain (Fig. 1), which has been employed widely for the
assessment of anti-inflammatory or analgesic properties
of new compounds [39]. Intraperitoneal administration
of poncirin 40 min prior to the acetic acid
administration considerably (p < 0.05) reduced the
number of abdominal writhing movements as compared
to vehicle-treated group (Fig. 1).
Poncirin reduces formalin-induced paw licking in both
phases
The anti-nociceptive effect of poncirin was also con-
firmed by using formalin test, which produces a biphasic
response, each phase represents distinct types of pain
[40]. The first phase, named as nociceptive phase, is a
result of direct stimulation of nociceptors and is medi-
ated centrally, while the second phase is an inflamma-
tory phase, caused by the local release of hyperalgesic
and inflammatory mediators [40]. Formalin injection
produced biphasic paw licking response with the first
phase ranged from 0 to 10 min, while the second phase
ranged from 10 to 30min. Administration of poncirin
40 min prior to formalin-induction significantly reduced
the paw licking response dose dependently in both early
phase (Fig. 2a) and late phase (Fig. 2b) respectively, how-
ever, the dose of 30 mg/kg showed maximum response
(p < 0.05). The positive control treated with piroxicam
(5 mg/kg) also showed the significant anti-nociceptive
effect in both phases.
Poncirin inhibits carrageenan-induced mechanical and
thermal hyperalgesia
The compound poncirin was tested in three different
doses (5 mg/kg, 15 mg/kg or 30 mg/kg, i.p) in first two
set of experiments and 30 mg/kg dose of poncirin pro-
duced significant analgesic responses when compared
with negative control groups, therefore, poncirin (30
mg/kg) was used in subsequent experiments. Next, the
anti-nociceptive effect of poncirin (30 mg/kg, i.p) was
assessed in carrageenan-induced acute inflammatory
pain model. Poncirin noticeably inhibited (p < 0.05) car-
rageenan-induced mechanical (Fig. 3a) and thermal
(Fig. 3b) hyperalgesia at given dose after 4 h of carra-
geenan injection. In vehicle-treated group marked in-
crease in pain sensitivity was observed in mechanical
(Fig. 3a) and thermal hyperalgesia (Fig. 3b). Whereas,
Table 1 the sequences of PCR primers
Genes Forward primer Reverse prime
β-actin TGAAGGTCGGTGTGAACGGATTTGGC CATGTAGGCCATGAGGTCCACCAC
TNF-α GTTCTATGGCCCAGACCCTCA GGCACCACTAGTTGGTTGTCTTTG
IL-1β TCC AGG ATG AGG ACA TGA GCAC GAA CGT CAC CCA GCA GGT TA
IL-6 CCA CTT CAC AAG TCG GAG GCT TA CCA GTT TGG TAG CAT CCA TCA TTT C
VEGF TTACTGCTGTACCTCCACC ACAGGACGGCTTGAAGATG
Nrf2 TGG GGA ACC TGT GCT GAG TCA CTG GAG ACC CCT TGG ACA CGA CTC AGT GAC CTC
HO-1 CACGCATATACCCGCTACCT CCAGAGTGTTCATTCGAGA
SOD2 GCGGTCGTGTAAACCTCAT GGTGAGGGTGTCAGAGTGT
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the dexamethasone used as positive control also inhib-
ited mechanical and thermal hyperalgesia (Fig. 3).
Poncirin inhibits carrageenan-induced mechanical
allodynia and paw edema
The poncirin treatment significantly inhibited carrageenan-
induced mechanical allodynia, while the maximum
increase in pain threshold (p < 0.05) was noticed with
escalated dose i.e. 30 mg/kg (Fig. 3c). The positive
control (dexamethasone 5 mg/kg, i.p) also exhibited
significant reduction in allodynic responses compared,
however, the negative control group showed
decreased in pain threshold and hypersensitivity to
the allodynic stimulus. Similarly, the poncirin admin-
istration markedly reversed the carrageenan-induced
paw swelling compared to the negative control group
(treated with carrageenan only) (Fig. 3d). Further-
more, the positive control group also significantly
inhibited the carrageenan-induced paw edema in mice
(Fig. 3d).
Fig. 2 Inhibition of formalin-induced paw licking and total time spent in paw licking was reduced by poncirin. The total time spent in paw
licking was observed for 0–10 min (a) and 10–30min (b) after formalin injection. Treatment with piroxicam (5 mg/kg, i.p) was used as a control.
Each column represents the mean ± SEM of 6–7 mice per group. *p < 0.05, **p < 0.01 and ***p < 0.001 denote the significant differences from the
negative control group
Fig. 1 Inhibition of abdominal writhing induced by acetic-acid as described in “Materials and methods”. The total numbers of writhing were
evaluated over the period of 30min. Each column represents the mean ± SEM of 6–7 mice per group. *p < 0.05, **p < 0.01 and ***p < 0.001
denote the significant differences from the negative control group
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Poncirin inhibits CFA-induced mechanical hyperalgesia
and allodynia
Next, the modulatory effect of poncirin was evaluated in
mechanical hyperalgesia and allodynia. In order to inves-
tigate the effects of poncirin in CFA-induced mechanical
hyperalgesia, animals were treated with poncirin (30 mg/
kg, i.p) 40 min prior to CFA injection. Poncirin signifi-
cantly increased pain thresholds in both mechanical
hyperalgesia test and allodynia at 2, 4 and 6 h after CFA
injection, showing the promising activity of poncirin in
acute case. Dexamethasone also significantly increased
the pain threshold as compared to negative control
(Fig. 4).
In order to investigate the chronic anti-inflammatory
and analgesic effects of poncirin on mechanical hyper-
algesia and allodynia, animals were treated daily for 6
days skipping day 5 after CFA injection. Poncirin (30
mg/kg, i.p) daily treatment significantly increased pain
thresholds throughout treatment period compared with
negative control (Fig. 4c and d) indicating the effective-
ness of poncirin in chronic inflammatory pain model.
The dose of the poncirin was skipped at day 5 to observe
the tolerance effect (whether the anti-inflammatory ef-
fect of the poncirin remains persistent while skipping
the dose or it should be administered daily to produce
its effect) as described previously [28]. However, the pon-
cirin treatment did not exhibited any tolerance effect and
the mechanical hyperalgesia and allodynia was reestab-
lished when the dose was skipped at day 5 (Fig. 4c & d).
Inhibition of thermal hyperalgesia and cold allodynia by
poncirin in CFA-induced pain model
In order to investigate the effects of poncirin in CFA-in-
duced thermal hyperalgesia and cold allodynia, animals
were treated with poncirin (30mg/kg, i.p) 40min prior to
CFA injection. Poncirin significantly inhibited acute
thermal hyperalgesia (Fig. 5a) at 2, 4 and 6 h after CFA in-
jection, showing the promising activity of poncirin. Dexa-
methasone treated group also significantly increased the
pain threshold as compared to negative control. For long-
term effects of poncirin on thermal hyperalgesia, animals
were treated daily for 6 days after CFA injection, skipping
day 5 for evaluation of tolerance effect (whether the anti-
inflammatory effect of the poncirin remains persistent
while skipping the dose or it should be administered daily
to produce its effect) of the drug on thermal hyperalgesia
as reported previously [28]. Poncirin (30mg/kg, i.p) daily
treatment significantly increased pain thresholds (Fig. 5b)
indicating the effectiveness of poncirin in chronic inflam-
matory pain model.
Fig. 3 Anti-hyperalgesic activities of poncirin in acute inflammatory pain model induced by carrageenan (a) inhibition of mechanical hyperalgesia,
(b) inhibition of thermal hyperalgesia, (c) inhibition of mechanical allodynia and (d) reduction in paw thickness. Each column represents the
mean ± SEM of 6–7 mice per group. *p < 0.05, **p < 0.01 and ***p < 0.001 denote the significant differences from the negative control group
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Similarly, poncirin significantly inhibited acute cold
allodynia (Fig. 5c) at 4 and 6 h after CFA injection. For
long-term effects of poncirin on cold allodynia, animals
were treated daily for 6 days after CFA injection. Pon-
cirin (30 mg/kg, i.p) daily treatment significantly in-
creased pain thresholds on day 4 and 6 compared with
negative control, indicating the effectiveness of poncirin
in chronic inflammatory pain model (Fig. 5c).
Poncirin inhibited CFA-induced paw edema
Poncirin inhibited paw edema induced by CFA in both
acute and chronic inflammation models. Administration
of poncirin significantly reduced the paw thickness at 2,
4 and 6 h after CFA-induced acute edema (Fig. 6a). For
the evaluation of long-term effects of poncirin in CFA-
induced paw edema, poncirin (30 mg/kg) treatment for
6 days showed significant inhibition of paw edema
compared to CFA treated group (Fig. 6b). Similarly, the
positive control (dexamethasone 5 mg/kg) also signifi-
cantly attenuated the acute paw edema 2, 4 and 6 h after
CFA administration, while the daily administration of
dexamethasone (5 mg/kg) for 6 days also markedly
attenuated the CFA-induced paw edema compared to
the negative control (Fig. 6b).
Poncirin doesn’t have any effect on the motor activity
of mice
Poncirin chronic administration does not effected the
motor function of the mice, which was evaluated by
Weights test and Kondziela’s screen tests utilized as a
screening tool in preliminary drug research for evalu-
ation of motor function (Fig. 7a and b) [33, 41]. Motor
function was altered in the CFA-treated group while
both poncirin and dexamethasone did not alter the
muscle strength both after acute and long-term adminis-
tration of drugs.
Body weight assessment
Each group of mice were weighted before the disease
induction with CFA. Similarly, the weight of mice were
also recorded at day 6 of the CFA administration at the
end of the experiment as shown (Additional file 1).
Poncirin reduced the production of NO in plasma after
CFA induction
The inhibitory effect of poncirin on NO production
in plasma was analyzed on day 6 of the CFA adminis-
tration using Griess reagent method as described
previously [28]. The CFA administration markedly
Fig. 4 Anti-hyperalgesic activities of poncirin in chronic inflammatory pain model induced by CFA (a) inhibition of acute mechanical hyperalgesia,
(b) inhibition of acute mechanical allodynia, (c) inhibition of chronic mechanical hyperalgesia and (d) inhibition of chronic mechanical allodynia.
Each data point represents the mean ± SEM of 6–7 mice per group. *p < 0.05, **p < 0.01 and ***p < 0.001 denote the significant differences from
the negative control group
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increased the production of NO in mice plasma at
day 6 of the administration. The poncirin (30 mg/kg)
treatment significantly attenuated the NO (almost
80%) production compared to the negative control
(only CFA treated group) (Fig. 8). Similarly, the dexa-
methasone-treated group also showed obvious
decrease in NO production (approximately 83%
decrease was noted in NO production) (Fig. 8).
Poncirin inhibits CFA-induced pro-inflammatory cytokines
production
To examine the effect of poncirin (30 mg/kg) on the
production of pro-inflammatory cytokines in CFA-
treated paw, qRT- PCR was performed. qRT-PCR results
showed increased expressions of TNF-α, IL-1β, IL-6 and
VEGF mRNA in CFA-induced mice paw tissue (Fig. 9a,
b, c and d). Whereas, poncirin treatment strikingly
Fig. 5 Anti-nociceptive activities of poncirin in thermal hyperalgesia and cold allodynia induced by CFA (a) inhibition of acute thermal hyperalgesia,
(b) inhibition of chronic thermal hyperalgesia and (c) inhibition of cold allodynia. Each data point represents the mean ± SEM of 6–7 mice per group.
*p < 0.05, **p < 0.01 and ***p < 0.001 denote the significant differences from the negative control group
Fig. 6 Anti-inflammatory activities of poncirin in paw induced by CFA (a) inhibition of acute paw edema and (b) inhibition of chronic paw
edema. Each data point represents the mean ± SEM of 6–7 mice per group. *p < 0.05, **p < 0.01 and ***p < 0.001 denote the significant
differences from the negative control group
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inhibited the mRNA expression levels of pro-algesic and
inflammatory cytokines such as TNF-α, IL-1β, IL-6 and
VEGF (Fig. 9).
Poncirin increased the expression levels of Nrf2, HO-1,
and SOD2 in CFA-induced inflammatory pain model
qRT-PCR was also used to investigate the effect of
poncirin treatment on expression levels of the phase II
antioxidant enzymes (HO-1 and SOD2). Nrf2 activates
antioxidant response element (ARE) that in turns is
responsible for the expression of phase II antioxidant
enzymes [42]. The mRNA expression levels of SOD2
(approximately 79% increase was noticed) and HO-1
(more than 5 times) was increased in poncirin treated
group as compared to CFA treated group (Fig. 10b and c).
Poncirin treatment up-regulated Nrf2 (100% increase)
expression level considerably (Fig. 10a).
Poncirin doesn’t cause hepatic or renal damage
Mice were treated daily with poncirin (30mg/kg, i.p) or
dexamethasone (5mg/kg, i.p) or vehicle for 6 days after in-
duction of inflammatory pain. The treatment with poncirin
and dexamethasone did not alter the hepatic and renal
functions (Table 2), thus signifies that poncirin administra-
tion did not produce any toxicity against these vital organs.
Poncirin inhibited infiltration of inflammatory cells and
soft tissue swelling after CFA induction
Histopathological analysis of tibiotarsal joints of right
hind paw showed a significant infiltration of immune
Fig. 7 (a) Effect of poncirin treatment on muscle strength and motor coordination of animals was measured by using inverted tray method at 0 h, 6 h
and day 6 as described in materials and method section. (b) Effect of poncirin treatment on muscle coordination of animals was measured by using
weight test at 0 h, 6 h, and day 6. Each column represents the means ± SEM of 6–7 mice per group. *p < 0.05, **p < 0.01 and ***p < 0.001 denote the
significant differences from the negative control group
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cells and synovial hyperplasia in CFA treated group,
while poncirin treated group showed a reduction of im-
mune cells infiltration and synovial hyperplasia (Fig. 11b).
The radiographic examination of the soft tissue showed
marked reduction in soft tissue swelling of the right hind
paw in those animals who were treated with the pon-
cirin, however, the animals challenged with CFA only
showed noticeable soft tissue swelling and bony erosion
(Fig. 11a).
Discussion
Inflammatory pain is a common chief complaint associ-
ated with many disease conditions including irritable
bowel syndrome, rheumatoid arthritis and osteoarthritis
[2]. The inflammation mediated pain trigger the induc-
tion of pro-inflammatory cytokines and activates several
signaling pathways such as NF-κB, MAPKs etc. Cur-
rently, several therapeutic approaches are employed to
treat the inflammatory pain such as NSAIDs and opioids
[43]. The chronic use of NSAIDs such as aspirin can
cause the GIT ulceration, while the prolonged use of
opioids is related with the development of tolerance, de-
pendence and respiratory depression [44–47]. All these
challenges necessitate the development and discovery
new molecules, which are safe, effective and associated
with less side effects profile. Since decades, medicinal
plants have been used for therapeutic purposes, as they
are effective and safe and offer a good source of new
chemical entity [44–47]. Poncirin is flavanone derivative
obtained from dried immature fruits of Poncirus trifoliata,
which was used to treat inflammation and asthma in an-
cient times [44–47]. Recent studies on poncirin have also
confirmed its anticancer and anti-inflammatory activity
[14]. In the current study, it was demonstrated that sys-
temic administration of poncirin in various inflammatory
pain models successfully alleviated pain associated with in-
flammation. The anti-hyperalgesic effects of poncirin in
inflammatory pain can be attributed to suppression of
pro-inflammatory cytokines including TNF-α, IL-1β and
IL-6, enhancing the expression of antioxidant genes and
enzymes (Nrf2, HO-1 and SOD2) respectively. Therefore,
the present study highlights the analgesic potential of
poncirin together with its safety since the systemic admin-
istration of poncirin did not present any renal, hepatic or
motor side effects.
Acetic acid-induced abdominal writhing is a simple
method for novel drugs screening in visceral pain [20].
Acetic acid administration causes the activation of
peritoneal macrophages and mast cells which leads to
local release cytokines such as TNF-α and IL-1β and
Fig. 8 Effect of treatment with poncirin on nitrite (NO) production determination in blood plasma. Each column represents the means ± SEM of
6–7 mice per group. *p < 0.05, **p < 0.01 and ***p < 0.001 denote the significant differences from the negative control group
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Fig. 10 (a) Effect of treatment with poncirin on protein expression of Nrf2, (b) HO-1 and (c) SOD2 in mice paw tissue. Each column represents
the means ± SEM of 6–7 mice per group. *p < 0.05, **p < 0.01 and ***p < 0.001 denote the significant differences from the negative control group
Fig. 9 (a) Effect of treatment with poncirin on mRNA expression levels of TNF-α, (b) IL-6, (c) IL-1β and (d) VEGF in mice paw tissue. The mice
were treated with poncirin (30 mg/kg, i.p), dexamethasone (5 mg/kg, i.p) or vehicle control as described in “Materials and methods”. Each column
represents the mean ± SEM of 6–7 mice per group. *p < 0.05, ** p < 0.01 and ***p < 0.001 denote the significant differences from the negative
control group
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other mediators like eicosanoids and sympathomimetic
amines [38]. Since poncirin administration inhibited
acetic acid-induced writhing markedly, it is likely that
the anti-nociceptive activity of poncirin might be con-
tributed due to its inhibitory activity cytokines produc-
tion. Similarly, the anti-nociceptive activity of poncirin
was also observed in formalin-induced tonic pain model.
The injection of formalin causes an intense and immedi-
ate increase in impulses transmission from C afferent
fibers and produce a diverse quantifiable behavior as
paw licking by the animal that indicates the intensity of
pain [48]. This test can also be used to determine the ef-
fect of new compounds on central and peripheral noci-
ceptive pathways as formalin injection causes biphasic
reaction consisting of early neurogenic phase and late in-
flammatory phase [49]. The early neurogenic phase of
formalin injection last from 0 to 10 min and is caused by
the release of neurotransmitters such bradykinin and
serotonin as well as molecules released from residents
cells causing the activation of transient receptor poten-
tial ankyrin 1 (TRPA1) on the surface of nociceptive
fibers [50]. The late inflammatory phase of formalin test
lasts from 10 to 30min and occurs because of release of
inflammatory cytokines including TNF-α, IL-1β, IL-6
and prostaglandins after administration of inflammatory
stimuli like formalin [51]. Poncirin inhibited both paw
licking and total time spent in paw licking in both
phases of formalin injection. Interestingly, poncirin ad-
ministration reduced the total spent in paw licking in
the first phase as compared the positive control, showing
its effect on the central pain pathways. The analgesic
potential of poncirin was also demonstrated in carra-
geenan- and CFA-induced acute and chronic inflamma-
tory pain models. Carrageenan and CFA are algogenic
substances and cause the local release of mediators, such
as prostanoids and cytokines, involved in the inflamma-
tory signs such as vasodilation, edema, and hyperalgesia
[52, 53]. Importantly, the systemic administration of
poncirin reduced both hyperalgesia and allodynia in both
carrageenan and CFA model with comparable results to
dexamethasone, which is a standard anti-inflammatory
drug, showing the anti-nociceptive potential of poncirin.
Carrageenan- and CFA-induced inflammatory pain are
well-accepted models of acute and chronic pain respect-
ively. The peripheral injection of algogenic substances
like carrageenan and CFA causes the release of numer-
ous nociceptive and inflammatory mediators, resulting
in the alteration of synaptic activity by increasing the
primary sensory fibers discharge and causing central
Fig. 11 Clinical appearance of right hind paws. (a) Radiographic evidence of right hind paw from (1) Vehicle control, (2) negative control group,
(3) positive control group and (4) poncirin treated group. Tissue swelling can be observed in the tibiotarsal region of CFA treated mice as
compared to poncirin treated mice. (b) Histopathological analysis of tibiotarsal joint from (1) vehicle control, (2) negative control group, (3)
positive control treated group and (4) poncirin treated group. Paw tissues were sectioned at 4 μm thickness, stained by hematoxylin-eosin and
observed with the microscope (40×). Note marked immune cell infiltration, synovial hyperplasia, in the vehicle-treated group as compared to
poncirin treated group
Table 2 Effect of poncirin on liver and kidney function
Sample Creatinine (mg/dL) GPT/ALT (UI/L) GOT/AST (UI/L)
Normal 0.4 ± 0.28 94 ± 1.41 141 ± 2.82
Dex 5 mg/kg 0.4 ± 0.22 94 ± 1.56 142 ± 1.25
Poncirin 30 mg/kg 0.4 ± 0.14 95 ± 2.12 144 ± 2.12
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pain sensitization by modifying neuroimmune cells [54].
In present study, systemic administration of flavanone
glycoside poncirin remarkably inhibited the mechanical,
thermal hyperalgesia and mechanical and cold allodynia
induced by carrageenan and CFA in both acute and
chronic inflammation models in mice. Poncirin in-
creased the pain threshold after 2 h of treatment and
its effects persisted until 6 h in the acute model and
until day 5 in the chronic model. The paw edema in-
duced by carrageenan and CFA was also significantly
reduced by poncirin. Because TNF-α, IL-1β and IL-6,
play a key role in inflammatory hyperalgesia, it may
be suggested that the anti-nociceptive effects of
poncirin are due to its ability to inhibit the release of
inflammatory cytokines [44].
NO is a well-established mediator of inflammation and
its production is related to the degree of inflammation
[55]. The expression of NO is under the influence of
iNOS gene, however, its production is also regulated by
the TNF-α, thus maintain the hyperalgesic state after the
inflammation and pain. The poncirin treatment signifi-
cantly reduced the levels of NO compared to the CFA-
induced group.
Inflammation is closely related to sensation of pain [5].
Following the local injection of CFA there is a release of
various inflammatory mediators including TNF-α, IL-1β
and IL-6. NO also contributes to the hyperalgesic state
by indirectly sensitizing the nociceptors through the pro-
duction of prostanoids such as PGE2. In addition, these
cytokines increase the synaptic transmission by directly
activating nociceptors [4]. In the present study, poncirin
also significantly reduced the expression of TNF-α, IL-
1β and IL-6 in CFA induced inflammatory pain, suggest-
ing that suppression of these pro-inflammatory cytokines
contributes to the anti-nociceptive activity of poncirin.
Vascular endothelial growth factor (VEGF) induces vas-
cular leakage by enhancing vascular permeability, thus
playing an important role in inflammation [56]. The
expression of inflammatory cytokines is, also induced by
VEGF indicating the role of VEGF in the production of
these hyperalgesic cytokines [56]. The poncirin treat-
ment significantly reduced the mRNA expression level
of the VEGF compared to the negative control group,
thus, indicating the potent anti-inflammatory role of the
poncirin.
Nrf2 is transcription factor responsible for the induc-
tion antioxidant enzymes including glutathione peroxid-
ase (GPx), Glutathione S transferase (GST) and HO-1
[42]. Nrf2 have multiple protective actions including
antioxidant activity by induction of antioxidant enzymes,
anti-inflammatory role in many diseases as well as pro-
tective action in wound healing [57, 58]. The protective
anti-inflammatory role of Nrf2 is attributed to inhibition
of expression of pro-inflammatory cytokines, iNOS and
COX-2 in early events of inflammation. HO-1 is one of
the major anti-inflammatory and cytoprotective en-
zymes, expression of which is controlled by Nrf2 [59].
The HO-1 expression is induced by many inflammatory
stimuli and increased inflammatory state was observed
in mice deficient with HO-1 emphasizing on the import-
ant role of HO-1 in inflammation resolution and hence
decreasing hyperalgesic state [60]. In the current study,
systemic administration of poncirin has shown to signifi-
cantly increased the expression of Nrf2 and induction of
HO-1, highlighting its importance in reducing the
inflammatory pain through Nrf2 mediated pathway.
Poncirin treatment also up-regulated the expression of
SOD2 (superoxide dismutase 2) following CFA-induced
inflammatory pain in mice. SOD2 is antioxidant enzyme
belonging to SOD family and plays important role in
body defense as antioxidant enzyme by modulating the
production of inflammatory cytokines [61]. SOD2 high
levels in the body inhibit the phospholipase-2 (PLA2)
overexpression and consequently inhibits the downstream
PGE2 production via NF-κB-dependent pathways [62],
thus, reduces the pain by reducing the inflammation.
To assess the toxic effect of poncirin on liver and
kidney, liver and kidney functions test were performed
using blood plasma. The poncirin treatment exhibits no
toxic effect on the liver and kidney. Similarly, to observe
any possible toxic effect on the animals, muscle strength
and coordination was assessed. The poncirin treatment
was not associated with any toxic effect on the muscle
strength and coordination.
Conclusion
Poncirin significantly reduced abdominal writhing in
acetic acid-induced visceral pain and also showed
remarkable results in both phases of formalin test. In
addition, poncirin administration also significantly
produced anti-allodynic and anti-hyperalgesic effects in
carrageenan- and CFA-induced models. Importantly,
chronic treatment with poncirin in CFA model did not
produce any side effects. Poncirin also reduced the NO
content and pro-inflammatory cytokines expression in-
cluding TNF-α, IL-1β and IL-6 in paw tissue. The
mRNA expression of VEGF was also inhibited by
poncirin, which correlates to reduction in paw edema
and increased pain thresholds in CFA induced inflam-
matory pain models. Poncirin also significantly increased
the antioxidant enzymes (HO-1 and SOD2) and tran-
scription factor (Nrf2), suggesting that protective role of
poncirin as well as multiple targets by which poncirin
modulates pain. Collectively, our data demonstrate the
analgesic potential of poncirin in acute and chronic
inflammatory pain conditions that still need an effective
and safe therapeutic option.
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Additional file 1: Figure S1. Body weight assessment. The weight of
animals at day 1 and day 7. (DOCX 59 kb)
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